Related Experiment Videos
[Cardiovascular diseases: toward an optimal use of clinical biological laboratories]
J M Boeynaems1, P Capel, E Serruys
1Département de Biologie Clinique, Hôpital Erasme, Bruxelles.
Insights
Early laboratory detection of cardiovascular disease risk factors can improve public health. Careful selection of cost-effective tests optimizes clinical lab resources for new diagnostic markers.
Area of Science:
- Clinical Chemistry
- Public Health
- Preventive Medicine
Context:
- Cardiovascular diseases (CVDs) are a leading cause of illness and death.
- Laboratory tests are crucial for early CVD risk factor detection.
- Widespread screening necessitates cost-effective test selection.
Purpose:
- To evaluate the cost-effectiveness of laboratory tests for cardiovascular disease risk factors.
- To advocate for the inclusion of new, informative biomarkers in routine screening.
- To optimize clinical laboratory resource allocation for public health benefit.
Summary:
- Cardiovascular diseases pose a significant public health burden.
- Judicious selection of laboratory tests balances cost and effectiveness.
- Potential savings can fund newer, more informative tests like plasma homocysteine, LDL-cholesterol, and lipoprotein (a).
Impact:
- Enhanced early detection of cardiovascular disease risk factors.
- Improved public health outcomes through timely preventive treatment.
- Potential for broader access to advanced diagnostic laboratory tests.
Abstract:
Cardiovascular diseases are a frequent cause of morbidity and mortality in our country. The early detection of risk factors by laboratory tests and the subsequent preventive treatment may have a substantial beneficial effect on public health. However, since these tests are performed on large populations, they must be chosen with caution, in order to optimise their cost/ effectiveness ratio. Savings obtained by the judicious use of the clinical lab could allow, already in 1996, the reimbursement of some new informative tests, like the plasma homocysteine and the LDL-cholesterol, and later, of the lipoprotein (a), all tests which are presently at the charge of the patient.